ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - Executive summary: A report of the American College of cardiology/American heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction)

Canadian Journal of Cardiology

Volumn 20, Issue 10, 2004, Pages 977-1025

  Antman, Elliott M ^a   Anbe, Daniel T ^a   Armstrong, Paul Wayne ^a   Bates, Eric R ^a   Green, Lee A ^a   Hand, Mary ^a   Hochman, Judith S ^a   Krumholz, Harlan M ^a   Kushner, Frederick G ^a   Lamas, Gervasio A ^a   Mullany, Charles J ^a   Ornato, Joseph P ^a   Pearle, David L ^a   Sloan, Michael A ^a   Smith Jr , Sidney C ^a   Alpert, Joseph S ^a   Anderson, Jeffrey L ^a   Faxon, David P ^a   Fuster, Valentin ^a   Gibbons, Raymond J ^a   Gregoratos, Gabriel ^a   Halperin, Jonathan L ^a   Hiratzka, Loren F ^a   Hunt, Sharon Ann ^a   Jacobs, Alice K ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANISTREPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; INSULIN; INSULIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; MORPHINE SULFATE; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; RETEPLASE; STREPTOKINASE; TADALAFIL; TENECTEPLASE; TIROFIBAN; UNINDEXED DRUG; UROKINASE; VALSARTAN; VERAPAMIL;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CLINICAL PROTOCOL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HEART CATHETERIZATION; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT PLANNING; ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; SEX DIFFERENCE; STANDARD; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

ADULT; AGE FACTORS; AGED; AMERICAN HEART ASSOCIATION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT EDUCATION; PATIENT SELECTION; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 4544264097     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (213)

1. Mehta RH, Montoye CK, Gallogly M, et al., for the GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-1276.
2. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003;289: 305-312.
3. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 2002; 287:1288-1294.
4. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1,2 and 3. J Am Coll Cardiol. 2000;36:2056-2063.
5. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: Amreican Heart Association 2003.
6. Wiviott SD, Morrow DA, Giugliano RP, et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and non-ST elevation myocardial infarction. J Am Coll Cardiol 2003;41:365A-366A.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
8. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147.
9. National, Heart, Lung, and Blood Institute. Act in Time to Heart Attack. Available at: http://:www.nhlbi.nih.gov/actintime, 2003. Accessedd May 15, 2003.
10. American College of Cardiology. Guidelines Applied in Practice. Available at: http://www.acc.org/gap/gap.htm. Accessed May 15, 2003.
11. American Heart Association. Get With the Guidelines. Available at http://www.americanheart.org/presenter.jhtml?identifier=1165. Accessed May 15, 2003.
12. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation. 2003;107:1463-1466.
13. Califf RM, Faxon DP. Need for centers to care for patients with acute coronary syndromes. Circulation. 2003;107:1467-1470.
14. Willerson JT. Editor's commentary: centers of excellence. Circulation. 2003;107:1471-1472.
15. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH publication No. 02-5125. Bethesda, Md: National Heart, Lung, and Blood Institute, 2002. Guidelines, Related Tools, and Patient Information, available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed April 12, 2003.
16. Dracup K, Alonzo AA, Atkins JM, et al. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med 1997;126:645-651.
17. Hedges JR, Feldman HA, Bittner V, et al, for the REACT Study Group. Impact of community intervention to reduce patient delay time on use of reperfusion therapy for acute myocardial infarction: Rapid Early Action for Coronary Treatment (REACT) trial. Acad Emerg Med. 2000;7: 862-872.
18. Canto JG, Zalenski RJ, Ornato JP, et al, for the National Registry of Myocardial Infarction 2 Investigators. Use of the emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2. Circulation 2002;106:3018-3023.
19. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the Trial: Rapid Early Action for Coronary Treatment (REACT). Coron Artery Dis. 2000;11:399-407.
20. Hutchings CB, Mann NC, Daya M, et al, for the Rapid Early Action for Coronary Treatment Study. Patients with chest pain calling 9-1-1 or self-transporting to reach definitive care: which mode is quicker? Am Heart J 2004;147:35-41.
21. Faxon D, Lenfant C. Timing is everything: motivating patients to call 9-1-1 at onset of acute myocardial infarction. Circulation. 2001;104: 1210-1211.
22. US Department of Health and Human Services, Public Health Service, National Institue of Health, National Heart, Lung, and Blood Institute. NIH publiction No.01-3313. September 2001. Available at: http://www.nhlbi.nih.gov/health/prof/heart/mi/provider.pdf. Accessed December 16, 2002.
23. Eisenberg MT, Topol EJ. Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med. 1996;156:1506-1510.
24. Fibrinolytic Therapy Trialist (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
25. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
26. Amrstrong PW, Colen D, Antman E. Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation. 2003;107: 2533-2537.
27. The American Heart Association in collabortion with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: Part 7: the era of reperfusion: section 1: acute coronary syndromes (acute myocardial infarction). Circulation. 2000;102(suppl I):I-172-I-203.
28. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ. 2003;327:22-26.
29. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J. 2002;21:275-283.
30. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108:2543-2549.
31. Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. Circulation. 1976; 54:624-628.
32. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
33. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J. Pharm Biomed Anal. 1999;21:383-392.
34. De Luca G, Suryapranata H, Zijlstra F, et al, for the ZWOLLE Myocardial Infarction Study Group. Sympton-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991-997.
35. Boersma E, Mercado N, Poldermans D, et al. Acute myocardial infarction. Lancet. 2003;361:847-858.
36. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment amd mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109: 1223-1225.
37. Boersma E, Mass AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reppraisal of the golden hour. Lancet 1996;348:771-775.
38. Zeymer U, Tebbe U, Essen R, et al, for the ALKK-Study Group. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. Am Heart J. 1999;137:34-38.
39. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Interventiion Trial. JAMA. 1993;270:1211-1216.
40. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
41. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol. 2001;88:1085-1090.
42. Williams DO. Treatment delayed is treatment denied. Circulation. 2004; 109:1806-1808.
43. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:28-66.
44. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elecation myocardial infarction: bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102: 2031-2037.
45. Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results form an international trial of 41,021 patients. Circulation. 1995;91:1659-1668.
46. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001;358:1571-1575.
47. Krumholz HM,Chen J, Wang Y, et al. Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. Circulation. 1999;99:1986-2992.
48. Granger CB, Goldberg RJ, Dabbous O, et al, for the Global Registry of AcuteCoronay Events Investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003; 163:2345-2353.
49. Magid DJ, Calonge BN, Rumsfeld Js, et al, for the National Registry of Myocardial Infarction 2 and 3 Investigators. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty therapy. JAMA. 2000;284:3131-3138.
50. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003;92:824-826.
51. Bonnefoy E, Lapostolle F, Leizorovicz A, et al., for the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet. 2002;360:825-829.
52. Steg PG, Bonnefoy E, Chabaud S. et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clincial trial. Circulation. 2003;108:2851-2856.
53. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplsty vs immediate thrombolysis in acute myocardial infarction: final result of the randomized national multicare trail: PRAGUE-2. Eur Heart J. 2003; 24:94-104.
54. Deleted in press.
55. Antman EM.General hospital management. In: Julian DG, Braunwald E. eds. Management of Acute Myocardial Infarction. London, England: WB Saunders 1994;42-44.
56. Lincoff AM, Califf RM, Van de Werf F, et al, for the Global Use of Strategies To Open Coronary Arteries (GUSTO) Investigators. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trail. JAMA. 2002;288:2130-2135.
57. Zijlstra F, Beukema WP, van't Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1997;29:908-912.
58. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol. 1993;22:376-380.
59. Grinfield L, Berrocal D, Bellardi J, et al. Fibrinolytics versus primary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina. J Am Coll Cardiol. 1996;27:A222. Abstract.
60. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680-684.
61. Widimsky P, Groch L, Zeízko M, et al. Multicentre randomized trial1 comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: the PRAGUE study. Eur Heart J. 2000;21:823-831.
62. de Boer MJ, Ottervanger JP, van't Hof AW, et al, for the Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol. 2002; 39:1723-1728.
63. Akhras F, Ousa AA, Swann G, et al. Primary coronary angioplasty or intravenous thrombolysis for patients with acute myocardial infarction? Acute and late follow-up results in a new cardiac unit. J Am Coll Cardiol. 1997;29:A235-A236.Abstract.
64. Deleted in press.
65. Grines CL, Browne KF, Marco J, et al. for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673-679.
66. Gibbons RJ, Holmes DR, Reeder GS, et al, for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993; 328:685-691.
67. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol. 1998;32:1687-1694.
68. García E, Elízaga J, Pérez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol. 1999;33:606-611.
69. The Global Use of Strategies to Open Occluded Cornary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
70. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardial. 2001; 37:985-991.
71. Schömig A, Katrati A, Dirschinger J, et al, for the Stent versus Thrombolysis for Occluded Coronary Arteries in Pateints with Acute Myocardial Infarction Study Investigators. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade comapred with tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 2000;343:385-391.
72. Vermeer F, Oude Ophuis AJ, vd Berg EJ et al. Prospective randomized comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999;82: 426-431.
73. Kastrati A, Mehilli J, Dirschinger J, et al, for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction (STOPAMI-2) Study. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomized trial. Lancet. 2002;359:920-925.
74. Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI-2 Investigators. Thrombolytic therapy ve primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943-1951.
75. Kastrati A, Mehilli J, Dirschinger J, et al, for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction (STOPAMI-2) Study. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol. 2002;39:1713-1719.
76. Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349: 733-742.
77. Hochman JS, Sleeper LA, Webb JG, et al, for the Should We Emergently Revascularize Occluded Coronaries ofr Cardiogenic Shock (SHOCK) Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341: 625-634.
78. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
79. Melandri G. The obsession with primary angioplasty. Circulation. 2003; 108:e1620.
80. Rogers WJ, Dean LS, Moore PB, et al, for the Alabama Registry of Myocardial Ischemia Investigators. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 1994;74:111-118.
81. Every NR, Parsons LS, Hlatky M, et al, for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med. 1996;335:1253-1260.
82. Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 1998; 31:1240-1245.
83. Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year result from a nationwide French survey. Circulation. 1999;99:2639-2644.
84. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies To Open Occluded Arteries in Acute Coronary Syndromes. (GUSTO-IIb) trial. Circulation. 1999;100:14-20.
85. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptomonset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000; 283:2941-2947.
86. Brodie BR, Stuckey TD, Hansen C, et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol. 2000;84:13-18.
87. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis form the primary angioplasty in myocardial infarction trials. Circulation. 2001;104:636-641.
88. Clements IP, Christian TF, Higano ST, et al. Residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation. 1993;88:1527-1533.
89. Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol. 2003;91:1401-1405.
90. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173-177.
91. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. Am J Cardiol. 1991;67:7-12.
92. Himbert D, Juliard JM, Steg PG, et al. Primary coronary angioplasty for acute myocardial infarction with contraindiction to thrombolysis. Am J Cardiol. 1993;71:377-381.
93. Zahn R, Schuster S, Schiele R, et al, for the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Cath Cardiovasc Interv. 1999;46:127-133.
94. Grzybowski M, Clements EA, Parsons L, et al. Morality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. 2003;290:1891-1898.
95. Lotfi M, mackie K, Dzavik V, et al. Impact of delays to cardiac surgery after failed angioplasty and stenting. J Am Coll Cardiol. 2004;43: 337-342.
96. Dehmer GJ, Gantt DS. Coronary intervention at hospitals without on-site cardiac surgery: are we Pushing the envelope too far? J Am Coll Cardiol. 2004;43:343-345.
97. Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998;31:1234-1239.
98. Rodríguez A, Bernardi V, Fernández M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction: Gianturco-Roubin in Acute Myocardial Infarction (GRAMI trail). Am J Cardial. 1998;81:1286-1291.
99. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart. 2001;85:667-671.
100. Saito S, Hosokawa G, Tanaka S, et al, for the PASTA Trial Investigators. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. Cathet Cardiovasc Interv. 1999;48:262-268.
101. Grines CL, Cox DA, Stone GW, et al, for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341:1949-1956.
102. Kawashima A, Ueda K, Nishida Y, et al. Quantitative angiographic analysis of restenosis of primary stenting using Wiktor stent for acute myocardial infarction: results from a multicenter randomized PRISAM study. Circulation. 1999;100(suppl I):I-856.Abstract.
103. Mailard L, Hamon M, Khalife K, et al, for the STENTIM-2 Investigators. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2000;35: 1729-1736.
104. Scheller B, Hennen B, Severin-Kneib S, et al. Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. Am J Med. 2001;110:1-6.
105. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88:297-301.
106. Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab and Device Investigation of Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
107. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004; 43:704-708.
108. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004; 147:E16.
109. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocadial infarction: TIMI II A results. JAMA. 1998;260:2849-2858.
110. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
111. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis: a decade later. Am Heart J. 2001;142:411-421.
112. Hochman JS, Sleeper LA, White HD, et al, for the SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock: one-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190-192.
113. Dzavik V, Sleeper LA, Cocke TP, et al, for the SHOCK Investigators. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J. 2003;24:828-837.
114. Dauerman HL, Goldberg RJ, Malinski M, et al. Outcomes and early revascularization for patients greater than or equal to 65 years of age with cardiogenic shock. Am J Cardiol. 2001;87:844-848.
115. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol. 2003;15:380-384.
116. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988;1:197-203.
117. Ross AM, Coyne KS, Reiner JS, et al, for the PACT (Plasminogen-activator Angioplasty Compatibility Trial). Investigators: A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol. 1999;34:1954-1962.
118. Montalescot G, Barragan P, Wittenberg O, et al, for the ADMIRAL (Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up). Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
119. Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single-vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. Circulation. 2003;108:1324-1328.
120. Scheller B, Hennen B, Hammer B, et al, for the SIAM III Study Group. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cariol. 2003;42:634-641.
121. Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366.
122. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. Lancet. 2002;359:1805-1811.
123. Alter DA, Tu JV, Austin PC, et al. Waiting times, revascularization modality, and outcomes after cute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. J Am Coll Cardiol. 2003;42:410-419.
124. Gupta M, Chang WC, Van de Werf F, et al, for the ASSENT II Investigators. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J. 2003;24:1640-1650.
125. Gibson CM, Karha J, Murphy SA, et al,for the TIMI Study Group. Early and long-term clinical outcomes associated with reinfarction following fibronolytic administration in the thrombolysis in myocardial infarction trials. J Am Coll Cardiol. 2003; 42:7-16.
126. Lablanche JM, Gueret P, Blanchard D, et al. Beneficial effects of very early PTCA in patients with intravenous thrombolysis for acute myocardial infarction: data from a nation-wide registry in France. Circulation. 2002; 106 (suppl II):II-630. Abstract.
127. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Prospective randomized trial comparing a routine invasive strategy within 24 hours to thrombolysis versus an ischemia-guided conservative approach to acute myocardial infarction with ST-segment elevation: The Gracia-1 trial. Lancet. 2004. In press.
128. ISIS-2(Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
129. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996:93:870-878.
130. White HD, Yusuf S. Issues regarding the use of heparin following streptokinase therapy. J Thromb Thrombolysis. 1995;2:5-10.
131. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-1863.
132. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624-629.
133. Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
134. Steinhubl SR, Berger PB, Mann JT III, et al, for the CREDO (Clopidogrel for the Reduction of Events During Observation) Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288:2411-2420.
135. CYPHER™ sirolimus-eluting coronary stent on RAPTORTM over-the-wire delivery system and CYPHER™ sirolimus-eluting coronary stent on RAPTORRAIL® rapid exchange delivery system [instructions for use]. Miami, FL; Cordis, a Johnson & Johnson Company; April 2003.
136. TAXUS: paclitaxel-eluting coronary stent system Monorail and over the wire coronary stent delivery system [directions for use]. Natick, MA; Boston Scientific; March 2004.
137. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: The Task Force on the Use of Antiplatelet Agent in Patients With Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J. 2004;25:166-181.
138. Levine GN, Kern MJ, Berger PB, et al, for the American Heart Association Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med. 2003;139:123-136.
139. Lee DP, Herity NA, Hiatt BL, et al, for the TIrofiban Given in the Emergency Room before Primary Angioplasty. Adjunctive platelet gly- coprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107:1497-1501.
140. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. JAMA. 2003;290:2041-2047.
141. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-597.
142. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
143. Malan SS. Psychosocial adjustment following MI: current views and nursing implications. J Cardiovasc Nurs. 1992;6:57-70.
144. Havik OE, Maeland JG. Patterns of emotional reactions after a myocardial infarction. J Psychosom Res. 1990;34:271-285.
145. Moser DK, Dracup K. Is anxiety early after myocardial infarction associated with subsequent ischemic and arrhythmic events? Psychosom Med. 1996;58:395-401.
146. Frasure-Smith N, Lespérance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol. 1995;14:388-398.
147. Chae Cu, Hennekens CH. Beta blockers. In: Hennekens CH, ed. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, Pa: WB Saunders 1999;79-94.
148. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;3132-3137.
149. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97:2202-2212.
150. Flather MD, Yusuf S, Køober L, et al. for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
151. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigations. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
152. Pitt B, Remme WJ, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
153. Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trail: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
154. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349;1893-1906.
155. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction: a matter of dose. N Engl J Med. 2003;349:1963-1965.
156. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m) Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation. 2000;101:101-108.
157. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guideline for the Clinical Use of Radionuclide Imaging). Available at: http://www.acc.org/clinical/guidelines/radio/rni_fulltext.pdf, 2003. Accessed January 15, 2004.
158. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Available at: www.acc.org/clinical/guidelines/echo/index.pdf,2003. Accessed January 15, 2004.
159. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation. 2002;106:2322-2327.
160. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med. 2002,108:374-380.
161. Hochman JS, Boland J, Sleeper KA, et al. for the SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an International Registry. Circulation. 1995;91:873-881.
162. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm, 2001. Accessed June 5, 2004.
163. Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med. 1994; 330:1211-1217.
164. Núñez L, de la Llana R, López Sendón J, et al. Diagnosis and treatment of subacute free wall ventricular rupture after infarction. Ann Thorac Surg. 1983;35:525-529.
165. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: Emergency Cardiac Care Committee and Subcommittees, American Heart Association: Part III: adult advanced cardiac life support. JAMA. 1992;268:2199-2241.
166. Campbell RWF. Arrhythmias, In: Julian DG. Braunwald E, eds. Management of Acute Myocardial Infarction. London, England: WB Saunders 1994;223-240.
167. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA, et al. Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc Drugs Ther. 2001;15:155-160.
168. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 guideline update: a report of the American College of Cardiology/American Heart Association Task Froce on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890-911.
169. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol. 2002;40:1703-1719.
170. Lamas GA, Ellenbogen KA. Evidence base for pacemeker mode selection: from physiology to randomized trials. Circulation. 2004;109: 443-451.
171. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;34:1262-1347.
172. Dyke C, Bhatia D. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization: management strategies for the cardiac surgeon. J Cardiovasc Surg (Torino). 1999;40:505-516.
173. Yusuf S, Zhao F, Mehta SR, et al. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition of aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
174. Physician's Desk Reference. Clopidogren package insert. Montvale, NJ: Medical Economics Co; 2756.
175. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Available at: http://www.acc.org/clinical/guidelines/exercise/exercise_clean.pdf, 2002. Accessed February 12, 2004.
176. Théroux P, Waters DD, Halphen C, et al. Prognostic value of exercise testing soon after myocardial infarction. N Engl J Med. 1979;301:341-345.
177. DeBusk RF, Kraemer HC, Nash E, et al. Stepwise risk stratification soon after acute myocardial infarction. Am J Cardiol. 1983;52:1161-1166.
178. Krone RJ, Gillespie JA, Weld FM, et al. Low-level exercise testing after myocardial infarction: usefulness in enhancing clinical risk stratification. Circulation. 1985;71:80-89.
179. Valentine PA, Frew JL, Mashford ML, et al. Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction: a double-blind study. N Engl J Med. 1974;291:1327-1331.
180. Rose J, Gilpin EA, Madsen EB, et al. A decision scheme of coronary angiography after acute myocardial infarction. Circulation. 1989;79:292-303.
181. Risk stratification and survival after myocardial infaction. N Engl J Med. 1983;309:331-336.
182. Zaret BL, Wackers TH, Terrin M, et al. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Resutls of the TIMI II Trial. J Am Coll Cardiol. 1991;17:214A. Abstract.
183. Roig E, Magriñá J, Garcia A, et al. Prognostic Value of exercise radionuclide angiography in low-risk acute myocardial infarction survivors. Eur Heart J. 1993;14:213-218.
184. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee ot Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Available at: www.acc.org/clinical/guidelines/stable/stable.pdf 2002. Accessed March 18, 2004.
185. O'Neill WW. "Watchful waiting" after thrombolysis: it's time for a re-evaluation. J Am Coll Cardiol. 2003;24:17-19.
186. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-1579.
187. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.
188. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ. 2004;328:693-697.
189. Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. Clin Cardiol. 1998;21:161-168.
190. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
191. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000;34:168-171.
192. van Es RF, Jonker JJ, Verheugt FW, et al, for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109-113.
193. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation. 2002;106:659-665.
194. Yusuf S, Sleight P, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
195. Fox KM, for the EURopean trial On Reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet. 2003;362:782-788.
196. Granger CB, McMurray JJ, Yusuf S, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
197. McMurray JJ, Ostergren J, Swedberg K, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362:767-771.
198. Yusuf S, Pfeffer MA, Swedberg K, et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-venticular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777-781.
199. Executive Council of the Heart Failure Society of America. Implications of recent clinical trials for heart failure performance measures. J Card Fail. 2004;10:4-5.
200. Deleted in press.
201. Antman E, Braunwald E. Acute myocardial infarction. In Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardivascular Medicine. 6th ed. Philadelphia, Pa: WB Saunders;2001:1114-1251. Chapter 5.
202. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation. 2003;107:1570-1575.
203. Chen J, Radford MJ, Wang Y, et al. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160:947-952.
204. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41:1178-1179.
205. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized Trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-615.
206. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
207. Rossouw JE, Anderson GL, Prentice RL, et al, for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
208. Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA. 1995;273:965-967.
209. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witzman JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation. In press.
210. Glassman AH, O'Connor CM, Califf RM, et al, for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709.
211. Swenson JR, O'Connor CM, Barton D, et al, for the Sertraline Antide-pressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol. 2003; 92:1271-1276.
212. Berkman LF, Blumenthal J, Burg M, et al, for the Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Dosease Patients (ENRICHD) Randomized Trial. JAMA. 2003; 289:3106-3116.
213. Alonzo AA. Acute myocardial infarction and posttraumatic stress disorder: the consequences of cumulative adversity. J Cardiovasc Nurs. 1999;13:33-45.